Home › NCT07532603

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age ≥ 18 years
2. Scalp biopsy consistent with LPP
3. Active and symptomatic LPP at screening and baseline-
4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2

Exclusion Criteria:

1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

About the study

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

What is being tested

• Oral Brepocitinib (drug)
• Placebo (drug)

Sponsor: Priovant Therapeutics, Inc. · Participants: 342 · Started: Mar 19, 2026

Contact the study team

• Clinical Trial Administrator · Phone: (212) 634-9743

Official record on ClinicalTrials.gov — NCT07532603

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.